Fig. 3. STING in non-hematopoietic tissues is important for the induction of GVHD after MHC-matched aHSCT.

(A) Weight loss, GVHD clinical score, and survival of chimeric (B6-WT donors/B6-STING^−/− recipients and B6-STING^−/− donors/B6-WT recipients) recipients after second transplant of LP/J BM and unseparated splenocytes (0.8×10⁶ T cells). Data pooled: 2 experiments (n=10 for CD45.1→WT, n=18 for STING^−/−→WT, n=15 for CD45.1→STING^−/−, n=8 for STING^−/−→STING^−/−). (B) Representative flow cytometry plots and frequency of donor T cells expressing an effector memory (CD44^hiCD62L^lo) or naïve (CD44^loCD62L^hi) phenotype in lymphoid tissues from chimeric recipients 8 weeks after second transplant with LP/J BM and unseparated splenocytes (0.8×10⁶ T cells). Data pooled: 2 experiments (n=6 per group, representing a total of 14 mice per group). (C) Representative histology and pathology score of ear skin from chimeric recipients 8 weeks after second aHSCT as in (A). Data representative of 2 experiments (n=8 per group). Scale bars=200μm. Chimeric groups compared using one-way ANOVA with Tukey’s multiple comparisons test for multiple groups. * p<0.05, ** p<0.01, *** p<0.001, ns=non-significant. Data are means ± SEM.